89 Article(s)
Pub. Date
#Total Relationship(s)
1 19333898 Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases. IDrugs 2009 Mar 6
2 20716772 The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. Blood 2010 Dec 2 2
3 21239804 Signal transduction inhibitor therapy for lymphoma. Hematology Am Soc Hematol Educ Program 2010 2
4 21279990 An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum 2011 Feb 1
5 21438742 The Syk kinase as a therapeutic target in leukemia and lymphoma. Expert Opin Investig Drugs 2011 May 1
6 21700926 The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2011 Sep 5
7 21926965 Involvement of the Syk-mTOR pathway in follicular lymphoma cell invasion and angiogenesis. Leukemia 2012 Apr 2
8 22035435 Promising new treatments for rheumatoid arthritis - the kinase inhibitors. Bull NYU Hosp Jt Dis 2011 1
9 22284392 Syk inhibition with fostamatinib leads to transitional B lymphocyte depletion. Clin Immunol 2012 Mar 2
10 22301676 Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels. Leukemia 2012 Jul 1
11 22362000 Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia 2012 Jul 4
12 22374444 [Involvement of Syk in pathology of systemic autoimmune disease]. Nihon Rinsho Meneki Gakkai Kaishi 2012 1
13 22492694 Inhibition of Syk activity by R788 in platelets prevents remote lung tissue damage after mesenteric ischemia-reperfusion injury. Am J Physiol Gastrointest Liver Physiol 2012 Jun 15 1
14 23055694 Kinase inhibitors: a new class of antirheumatic drugs. Drug Des Devel Ther 2012 1
15 23151054 Rational design of highly selective spleen tyrosine kinase inhibitors. J Med Chem 2012 Dec 13 1
16 23190017 Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies. Br J Clin Pharmacol 2013 Jul 4
17 23284223 Fostamatinib Disodium. Drugs Future 2011 1
18 23398911 Syk-induced phosphatidylinositol-3-kinase activation in Epstein-Barr virus posttransplant lymphoproliferative disorder. Am J Transplant 2013 Apr 1
19 23599436 Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis 2014 May 1
20 23861534 Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2013 Sep 2
21 24323900 Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor. Clin Cancer Res 2014 Feb 1 5
22 24329544 The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation. Br J Pharmacol 2014 May 2
23 24555683 Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 - 2013. Expert Opin Ther Pat 2014 May 1
24 24659719 A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor. Oncotarget 2014 Feb 28 1
25 24700868 Spleen tyrosine kinase inhibition attenuates autoantibody production and reverses experimental autoimmune GN. J Am Soc Nephrol 2014 Oct 2
26 24779514 Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase. J Med Chem 2014 May 8 1
27 24828076 Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia. Sci Transl Med 2014 May 14 1
28 24895144 Exposure vs. response of blood pressure in patients with rheumatoid arthritis following treatment with fostamatinib. J Clin Pharmacol 2014 Dec 1
29 25065010 The active metabolite of spleen tyrosine kinase inhibitor fostamatinib abrogates the CD4⁺ T cell-priming capacity of dendritic cells. Rheumatology (Oxford) 2015 Jan 4
30 25074688 OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy. Ann Rheum Dis 2015 Dec 1
31 25223809 Ginkgolide B inhibits platelet release by blocking Syk and p38 MAPK phosphorylation in thrombin-stimulated platelets. Thromb Res 2014 Nov 5
32 25280085 Pharmacokinetic-pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA). J Clin Pharmacol 2015 Mar 4
33 25388373 Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma. Int J Cancer 2015 Jun 15 5
34 25632006 Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells. J Immunol 2015 Mar 1 2
35 25748087 Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia. Clin Cancer Res 2015 Jun 1 9
36 25852057 Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. Blood 2015 Jun 25 2
37 26116555 The Syk Inhibitor Fostamatinib Decreases the Severity of Colonic Mucosal Damage in a Rodent Model of Colitis. J Crohns Colitis 2015 Oct 1
38 26148346 Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model. Clin Exp Rheumatol 2015 Jul-Aug 6
39 26514315 Effects of Fostamatinib on the Pharmacokinetics of Digoxin (a P-Glycoprotein Substrate): Results From in Vitro and Phase I Clinical Studies. Clin Ther 2015 Dec 1 4
40 26516588 Prevention of fostamatinib-induced blood pressure elevation by antihypertensive agents. Pharmacol Res Perspect 2015 Oct 1
41 26700956 Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure. Drug Metab Dispos 2016 Mar 6
42 26739683 Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies. Drugs R D 2016 Mar 5
43 26891724 Atheroprotection through SYK inhibition fails in established disease when local macrophage proliferation dominates lesion progression. Basic Res Cardiol 2016 Mar 1
44 27163495 Effects of Fostamatinib on the Pharmacokinetics of the CYP2C8 Substrate Pioglitazone: Results From In Vitro and Phase 1 Clinical Studies. Clin Pharmacol Drug Dev 2016 May 2
45 27476075 Spleen Tyrosine Kinase: A Crucial Player and Potential Therapeutic Target in Renal Disease. Nephron 2016 1
46 27858108 Effects of ranitidine (antacid), food, and formulation on the pharmacokinetics of fostamatinib: results from five phase I clinical studies. Eur J Clin Pharmacol 2017 Feb 1
47 28011996 The kinase inhibitors R406 and GS-9973 impair T cell functions and macrophage-mediated anti-tumor activity of rituximab in chronic lymphocytic leukemia patients. Cancer Immunol Immunother 2017 Apr 1
48 28116513 Repeatability and response to therapy of dynamic contrast-enhanced magnetic resonance imaging biomarkers in rheumatoid arthritis in a large multicentre trial setting. Eur Radiol 2017 Sep 1
49 28391340 Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond. Nephrol Dial Transplant 2017 Jan 1 2
50 28460620 CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death. Curr Cancer Drug Targets 2018 1